(+)-ALPHA-DIHYDROTETRABENAZINE FOR THE TREATMENT OF MOVEMENT DISORDERS
Patent Information
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- ADEPTIO PHARMA
- Filing Date
- 2018-03-29
- Publication Date
- 2026-07-15
AI Technical Summary
Current treatments for hyperkinetic movement disorders, such as Tourette's syndrome, are ineffective in suppressing tics across all patients and often come with dose-related side effects like depression and parkinsonism, with the therapeutic effects and isomer-specific activities of dihydrotetrabenazine being unclear.
Low doses of (+)-α-dihydrotetrabenazine are administered to effectively treat movement disorders without significant side effects by blocking a specific percentage of VMAT2 proteins, avoiding the need for prodrugs like Valbenazine and maintaining plasma levels below 15 ng/mL for 8 hours.
Low doses of (+)-α-dihydrotetrabenazine provide therapeutic benefits for hyperkinetic disorders like Tourette's syndrome while minimizing side effects, achieving VMAT2 blocking without causing parkinsonism or depression.